Skip to main navigation Skip to search Skip to main content

Danaparoid-sodium for dialysis in heparin-associated thrombocytopenia

  • Tel Aviv Sourasky Medical Center

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Danaparoid sodium is an antithrombin composed of 3 glycosaminoglycans: heparan sulfate, dermatan sulfate and chondroitin sulfate. Similar to heparin, danaparoid operates by activating antithrombin 3, but does not contain heparin or heparin fragments, and is therefore antigenically distinct. Danaparoid has been advocated as a safe and effective anticoagulant for heparin-associated thrombocytopenia. However, there is little experience in its use as a substitute for heparin in hemodialysis. We report 2 men, aged 82 and 73 years, respectively, who developed thrombocytopenia while undergoing hemodialysis with heparin, and who subsequently underwent successful dialysis with danaparoid. There was a rise in platelet levels in both while receiving danaparoid, and dialysis was completed without hemorrhagic or thrombotic complications. Danaparoid is a safe and effective substitute for heparin, and may be used as an anticoagulant in hemodialysis.

Original languageEnglish
Pages (from-to)361-364+419
JournalHarefuah
Volume136
Issue number5
StatePublished - 1 Mar 1999
Externally publishedYes

Fingerprint

Dive into the research topics of 'Danaparoid-sodium for dialysis in heparin-associated thrombocytopenia'. Together they form a unique fingerprint.

Cite this